Can the first new tuberculosis drugs in five decades make treatment faster and less dangerous for the hundreds of thousands of people living with drug-resistant strains of the world’s deadliest infectious disease?
A cross-border, cross-sectoral clinical trial has passed a major milestone on the road to answering that question.
On Oct. 18, the endTB consortium, a partnership between Partners In Health, Médecins sans Frontières, Interactive Research & Development and financial partner UNITAID, announced that 750 patient volunteers from four continents have enrolled in a trial that aims to find effective, safer, and shorter treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that no longer responds to standard medications.
